Literature DB >> 23090085

How promiscuous are pharmaceutically relevant compounds? A data-driven assessment.

Ye Hu1, Jürgen Bajorath.   

Abstract

Given the increasing notion of target promiscuity of bioactive compounds and polypharmacological drug behavior, a detailed analysis of publicly available compound activity data from medicinal chemistry sources was carried out to determine and quantify the degree of promiscuity of active compounds across all known human target families. The results are surprising. Approximately 62% of currently available compounds with high-confidence activity data are only annotated with a single biological target, whereas 36% are known to act against multiple targets within the same family (i.e., closely related targets). However, only ~2% of bioactive compounds are promiscuous across different target families. Thus, despite general data sparseness, these findings indicate that highly promiscuous bioactive compounds only rarely occur. Because pharmaceutically relevant active compounds represent the pool from which drug candidates emerge, one might extrapolate from these results and conclude that there is a low statistical probability to obtain drugs that act against multiple targets belonging to distinct families.

Entities:  

Mesh:

Year:  2012        PMID: 23090085      PMCID: PMC3535109          DOI: 10.1208/s12248-012-9421-y

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  22 in total

Review 1.  Drug repositioning: identifying and developing new uses for existing drugs.

Authors:  Ted T Ashburn; Karl B Thor
Journal:  Nat Rev Drug Discov       Date:  2004-08       Impact factor: 84.694

Review 2.  Novel computational approaches to polypharmacology as a means to define responses to individual drugs.

Authors:  Lei Xie; Li Xie; Sarah L Kinnings; Philip E Bourne
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-10-17       Impact factor: 13.820

3.  Global mapping of pharmacological space.

Authors:  Gaia V Paolini; Richard H B Shapland; Willem P van Hoorn; Jonathan S Mason; Andrew L Hopkins
Journal:  Nat Biotechnol       Date:  2006-07       Impact factor: 54.908

Review 4.  Can we rationally design promiscuous drugs?

Authors:  Andrew L Hopkins; Jonathan S Mason; John P Overington
Journal:  Curr Opin Struct Biol       Date:  2006-01-25       Impact factor: 6.809

5.  A small molecule-kinase interaction map for clinical kinase inhibitors.

Authors:  Miles A Fabian; William H Biggs; Daniel K Treiber; Corey E Atteridge; Mihai D Azimioara; Michael G Benedetti; Todd A Carter; Pietro Ciceri; Philip T Edeen; Mark Floyd; Julia M Ford; Margaret Galvin; Jay L Gerlach; Robert M Grotzfeld; Sanna Herrgard; Darren E Insko; Michael A Insko; Andiliy G Lai; Jean-Michel Lélias; Shamal A Mehta; Zdravko V Milanov; Anne Marie Velasco; Lisa M Wodicka; Hitesh K Patel; Patrick P Zarrinkar; David J Lockhart
Journal:  Nat Biotechnol       Date:  2005-02-13       Impact factor: 54.908

6.  Conciliating binding efficiency and polypharmacology.

Authors:  Jordi Mestres; Elisabet Gregori-Puigjané
Journal:  Trends Pharmacol Sci       Date:  2009-08-31       Impact factor: 14.819

7.  The properties of known drugs. 1. Molecular frameworks.

Authors:  G W Bemis; M A Murcko
Journal:  J Med Chem       Date:  1996-07-19       Impact factor: 7.446

8.  Structural insights into the molecular basis of the ligand promiscuity.

Authors:  Noé Sturm; Jérémy Desaphy; Ronald J Quinn; Didier Rognan; Esther Kellenberger
Journal:  J Chem Inf Model       Date:  2012-09-05       Impact factor: 4.956

9.  Methods for drug discovery: development of potent, selective, orally effective cholecystokinin antagonists.

Authors:  B E Evans; K E Rittle; M G Bock; R M DiPardo; R M Freidinger; W L Whitter; G F Lundell; D F Veber; P S Anderson; R S Chang
Journal:  J Med Chem       Date:  1988-12       Impact factor: 7.446

10.  Reorganizing the protein space at the Universal Protein Resource (UniProt).

Authors: 
Journal:  Nucleic Acids Res       Date:  2011-11-18       Impact factor: 16.971

View more
  12 in total

1.  Structural and Activity Profile Relationships Between Drug Scaffolds.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  AAPS J       Date:  2015-02-20       Impact factor: 4.009

2.  Enhancing Molecular Promiscuity Evaluation Through Assay Profiles.

Authors:  Sorin Avram; Ramona Curpan; Alina Bora; Cristian Neanu; Liliana Halip
Journal:  Pharm Res       Date:  2018-10-18       Impact factor: 4.200

3.  What is the likelihood of an active compound to be promiscuous? Systematic assessment of compound promiscuity on the basis of PubChem confirmatory bioassay data.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  AAPS J       Date:  2013-04-19       Impact factor: 4.009

4.  Many approved drugs have bioactive analogs with different target annotations.

Authors:  Ye Hu; Eugen Lounkine; Jürgen Bajorath
Journal:  AAPS J       Date:  2014-05-29       Impact factor: 4.009

5.  Systems and Network Pharmacology Approaches to Cancer Stem Cells Research and Therapy.

Authors:  Irfana Muqbil; Ginny W Bao; Rkya El-Kharraj; Minjel Shah; Ramzi M Mohammad; Fazlul H Sarkar; Asfar S Azmi
Journal:  J Stem Cell Res Ther       Date:  2012-12-16

6.  Quantifying the tendency of therapeutic target proteins to bind promiscuous or selective compounds.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  PLoS One       Date:  2015-05-22       Impact factor: 3.240

7.  High-resolution view of compound promiscuity.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  F1000Res       Date:  2013-06-27

8.  A simple mathematical approach to the analysis of polypharmacology and polyspecificity data.

Authors:  Gerry Maggiora; Vijay Gokhale
Journal:  F1000Res       Date:  2017-06-06

Review 9.  Metabolomics and systems pharmacology: why and how to model the human metabolic network for drug discovery.

Authors:  Douglas B Kell; Royston Goodacre
Journal:  Drug Discov Today       Date:  2013-07-26       Impact factor: 7.851

Review 10.  Entering the 'big data' era in medicinal chemistry: molecular promiscuity analysis revisited.

Authors:  Ye Hu; Jürgen Bajorath
Journal:  Future Sci OA       Date:  2017-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.